YD Bio Ltd (YDES)
Healthcare · NGM
Fundamentals
Valuation and ratings
YD Bio Ltd trades at USD2.24, which is 104% below the USD4.57 our discounted cash flow model puts on the business. On that measure alone it screens as undervalued, though a DCF is an argument rather than a measurement, and the market is frequently right about why something is cheap.
Our moat model scores it 26 out of 100, which is little in the way of a moat. A moat is a structural reason competitors cannot take the profits away, and it matters more to a long holding period than any single quarter's numbers do.
About YD Bio Ltd
YD Bio Limited a biopharmaceutical company focuses on blood-based cancer detection and develops stem cell- and exosome-based therapeutics to transform the treatment of spectrum of diseases with unmet medical needs. The company is based in Taipei, Taiwan.
YDES passes 3 of our 30 screens today
Each screen prints the exact criteria it used, and the circumstances in which it is wrong.
Common questions
Is YD Bio Ltd (YDES) undervalued?
Against our discounted cash flow estimate of USD4.57, YDES at USD2.24 is 104% below fair value. That is one model's answer, not a recommendation, and most of a DCF's output sits in a terminal value nobody can forecast.
The full research page for YDES, with financial statements, ownership detail, peer comparison and alerts, is free inside the app.
Data from company filings, exchange quotes and SEC EDGAR 13F disclosures. Quotes are delayed. Metrics we do not have are left out rather than estimated. Educational information, not financial advice.